Next 10 |
home / stock / lgnd / lgnd articles
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contr...
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation...
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced t...
On May 15, a recent SEC filing unveiled that Matthew E Korenberg, President & Chief Operating at Ligand Pharmaceuticals (NASDAQ:LGND) made an i...
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...
Investors might want to bet on Ligand Pharmaceuticals (NASDAQ: LGND), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating...
Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimat...
A significant insider transaction involving the exercise of company stock options was reported on March 27, by Todd C Davis, Chief Executive Office...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...